Scientific

Event Publication Document
EMPATHY: A Ph2 3 Randomized, Placebo Controlled Trial Evaluating Safety and Efficacy of Ensovibep in Ambulatory COVID 19 Patients
CD3-slow release DARPin® (CD3-SRD) concept – a smart solution for reducing cytokine release syndrome while maintaining optimal anti-tumor efficacy
MP0317: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo
pMHC: Application of the DARPin® technology for specific targeting of tumor-associated MHC class I:peptide complexes
Prodrug: A solution to T-cell engager toxicity: An anti-CD3 Prodrug DARPin (CD3-PDD) shows no toxicity, but potent anti-tumor activity in a humanized mouse model
AML: Immunomodulatory Agents and Interventions

Investors